NM_000329.3(RPE65):c.131G>A (p.Arg44Gln) is a missense variant predicted to replace arginine with glutamine at amino acid p.44. This variant is present in gnomAD v.4.1.0 at a GrpMax allele frequency of 0.00008443, with 13 alleles / 91,066 total alleles in the South Asian population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 4 probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 point, PMID: 20079931, PMID: 20683928, PMID: 25775262, PMID: 31960602). This variant has also been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.3(RPE65):c.271C>T (p.Arg91Trp) variant suspected in trans (0.5 points, PMID: 20079931), which was previously classified pathogenic by the ClinGen LCA / eoRD VCEP (1.5 total points, PM3). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts), onset before the age of 5 years (1 pt), strong night blindness, light-seeking behavior (1 pt), absent electroretinogram responses from both rods (0.5 pts) and cones (1 pt), abnormal color vision, reduced central visual acuity (1 pt), hyperopia, esotropia, discrete retinal vessel attenuation in the context of a normal fundus, very small white intraretinal flecks in mid- and far periphery (2 pts), visual field constriction (1 pt), obesity, mild mental retardation, and autism, which together are highly specific for RPE65-related recessive retinopathy (total 8 points, PMID: 20683928, PP4_Moderate). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 2 similarly affected relatives, with the variant present in the homozygous state (PP1_Moderate; PMID: 25775262). The computational predictor REVEL gives a score of 0.971, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited 0-2% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD VCEP PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PMID: 16150724, PMID: 19431183, PS3_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3, PP1_Moderate, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).